Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-27
2007-03-27
Tucker, Zachary C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000, C544S237000
Reexamination Certificate
active
10426147
ABSTRACT:
A compound of formula:or an isomer, salt, solvate, chemically protected form, or prodrug thereof, wherein A and B together represent an optionally substituted, fused aromatic ring;RLis a C5-7aryl group substituted in the meta position by the group R2, and optionally further substituted; wherein R2is selected from:and its use as a pharmaceutical, in particular for the treatment of diseases ameliorated by inhibiting the activity of PARP.
REFERENCES:
patent: 3813384 (1974-05-01), Vogelsang et al.
patent: 4665181 (1987-05-01), Thomas et al.
patent: 4841047 (1989-06-01), Engel et al.
patent: 5032617 (1991-07-01), Lee et al.
patent: 5041653 (1991-08-01), Lee et al.
patent: 5215738 (1993-06-01), Lee et al.
patent: 5556856 (1996-09-01), Engel et al.
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5648355 (1997-07-01), Theoharides
patent: 5874444 (1999-02-01), West
patent: 5886178 (1999-03-01), Allen et al.
patent: 6197785 (2001-03-01), Jackson et al.
patent: 6340684 (2002-01-01), Napoletano et al.
patent: 6426415 (2002-07-01), Jackson et al.
patent: 6476048 (2002-11-01), Szabo et al.
patent: 6498160 (2002-12-01), Napoletano et al.
patent: 6514983 (2003-02-01), Li
patent: 6514984 (2003-02-01), Watanabe
patent: 6635642 (2003-10-01), Jackson et al.
patent: 6677333 (2004-01-01), Seko et al.
patent: 2002/0183325 (2002-12-01), Martin et al.
patent: 2005/0059663 (2005-03-01), Martin et al.
patent: 2005/0080096 (2005-04-01), Ishida et al.
patent: 2005/0227919 (2005-10-01), Kudos
patent: 2143745 (1973-03-01), None
patent: 3813531 (1988-04-01), None
patent: 287 032 (1991-02-01), None
patent: 0030861 (1981-06-01), None
patent: 0269968 (1988-06-01), None
patent: 0 355 570 (1990-02-01), None
patent: 0389995 (1990-10-01), None
patent: 0502575 (1992-09-01), None
patent: 0 590 551 (1994-06-01), None
patent: 0634404 (1995-01-01), None
patent: 699754 (1996-03-01), None
patent: 705903 (1996-04-01), None
patent: 0 792 643 (1997-09-01), None
patent: 2 262 513 (1975-09-01), None
patent: 721286 (1955-01-01), None
patent: 2384776 (2004-03-01), None
patent: MI98A001671 (1999-04-01), None
patent: 54156526 (1979-12-01), None
patent: 58164577 (1983-09-01), None
patent: 62252774 (1987-11-01), None
patent: WO 91/18591 (1991-12-01), None
patent: WO 93/14086 (1993-07-01), None
patent: WO 94/10151 (1994-05-01), None
patent: WO 95/24379 (1995-09-01), None
patent: WO 96/19225 (1996-06-01), None
patent: WO 98/43477 (1998-10-01), None
patent: WO 98/51308 (1998-11-01), None
patent: WO 99/08680 (1999-02-01), None
patent: WO 99/11624 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/44612 (1999-09-01), None
patent: WO 99/47494 (1999-09-01), None
patent: WO 00/05219 (2000-02-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 00/44726 (2000-08-01), None
patent: WO 00/67734 (2000-11-01), None
patent: WO 01/12199 (2001-02-01), None
patent: WO 01/16136 (2001-03-01), None
patent: WO 01/16137 (2001-03-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO 01/23390 (2001-04-01), None
patent: WO 01/57038 (2001-08-01), None
patent: WO 01/79184 (2001-10-01), None
patent: WO 01/85686 (2001-11-01), None
patent: WO 01/85687 (2001-11-01), None
patent: WO 01/87845 (2001-11-01), None
patent: WO 01/90077 (2001-11-01), None
patent: WO 02/36576 (2002-05-01), None
patent: WO 03/070726 (2002-05-01), None
patent: WO 02/44157 (2002-06-01), None
patent: WO 02/068407 (2002-09-01), None
patent: WO 02/090334 (2002-11-01), None
patent: WO 02/094790 (2002-11-01), None
patent: WO 03/007959 (2003-01-01), None
patent: WO 03/051879 (2003-06-01), None
patent: WO 03/055865 (2003-07-01), None
patent: WO 03/057145 (2003-07-01), None
patent: WO 03/063874 (2003-08-01), None
patent: WO 03/070707 (2003-08-01), None
patent: WO 03/080581 (2003-10-01), None
patent: WO 03/093261 (2003-11-01), None
patent: WO 2004/080976 (2004-09-01), None
patent: WO 2005/053662 (2005-06-01), None
Hawley's Condensed Chemical Dictionary, 13th ed. pp. 716 and 825 © 1997 by Van Nostrand Reinhold.
Virag and Szabo, “The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors” Pharmacological Reviews, vol. 54(3) pp. 375-429 (2002).
Bowman et al, “Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro” British Journal of Cancer, vol. 84(1), pp. 106-112 (2001).
Griffin et al, “The role of inhibitors of poly (ADP-ribose) polymerase as resistance-modifying agents in cancer therapy” Biochim vol. 77, pp. 408-422 (1995).
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
West, Anthony R. “Solid State Chemistry and its Applications” Wiley, New York, pp. 358 and 365 (1988).
Gaken et al, “Efficient Retroviral Infection of Mamallian Cells Is Blocked by Inhibition of Poly(ADP-Ribose) Polymerase Activity” Journal of Virology, vol. 70(6), pp. 3992-4000 (1996).
Banasik, Marek, et al., “Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono(ADP-Ribosyl) transferase,”J. Biol. Chem., 1569-1575 (1992).
Ben-Hur, E., et al..,British J. Cancer, 49 (Suppl. VI), 39-42 (1984).
Berge, Stephen M., et al., “Pharmaceutical Salts,”J. Pharma. Sci., 66:1, 1-19 (Jan. 1977).
Berger, Nathan A., “Poly(ADP-ribose) in the cellular response to DNA damage,”Radiation Research., 101, 4-14 (1985).
Bold, Guido, et al., “New anilinophtalazines as potent and orally well absorbed inhibitors of the FEBF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis,”J. Med. Chem., 43:12, 2310-2323 (2000).
Burzio, Luis, et al., “Poly (adnenosine diphosphoribose) synthase activity of isolated nuclei of normal and leukemic leukocytes (38930),”Proceed. Soc. Exp. Biol. Med., 149, 933-938 (1975).
Cantoni, Orazio, et al., “Hydrogen peroxide insult in cultured mammalian cells: relationships between DNA single-strand breakage, poly (ADP-ribose) metabolism and cell killing,”Biochimica et Biophysica Acta., 1014, 1-7 (1989).
Cosi, C., “Poly (ADP-ribose) polymerase: early involvement in glutamate-induced neurotoxicity in cultured cerebellar granule cells,”J. Neurosci. Research, 39, 38-46 (1994).
D'Adda Di Fagagna, Fabrizio, et al., “Functions of poly (ADP-ribose) polymerase in controlling telomere length and chromosomal stability,”Nature Genetics, 23(1), 76-80 (Sep. 1999).
D'Amours, Damien, et al., “Poly (ADP-ribosyl)ation reactions in the regulation of nuclear functions,”Biochem. J., 342, 249-268 (1999).
Durkacz, Barbara W., et al., “(ADP-ribose)nparticipates in DNA excision repair,”Nature, 283:7.
El-Tamaty, El-Sayed H., et al., “Synthesis and biological activity of some 4-benzyl-192H)-phthalazinone derivatives,”Indian J. of Chem. (and abstract), 35B, 1067-1072 (Oct. 1996).
Fuska, J., et al., “New Cytotoxic and antitumor agents,” Chemical Abstracts, 104:102050 (1986).
Gäken, Joop A., et al., “Efficient retroviral infection of mammalian cells is blocked by inhibition of poly (ADP-ribose) polymerase activity,”J. Virology, 70:6, 3992-4000 (Jun. 1986).
Hall, Iris H., et al., “Cytotoxicity of imides-N-alkyl semicarbazones, thiosemiicarbazones, acetylhydrazones and related derivatives,”Anti-Cancer Drugs(and abstract 122:204573), V.6, 147-153 (1995).
Hirai, Kiyoshi, et al., “Aberration of poly (adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers,”Cancer Research43, 3441-3446 (Jul. 1983).
Kawamura, Ikuo, et al., “Ponalrestat, an aldose reductase inhibitor,” Chemi
Barr Martin Niall Morrison
Cockcroft Xiao-Ling
Dixon Lesley
Eversley Penny Jane
Hoare Janet
KuDOS Pharmaceuticals Limited
Maybridge plc
Michael & Best & Friedrich LLP
Tucker Zachary C.
LandOfFree
Phthalazinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phthalazinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phthalazinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3771500